BioCentury
ARTICLE | Finance

Anti-anti-wound healing

VCs double-down on CoDa's novel approach to wound healing

May 2, 2011 7:00 AM UTC

Conventional wisdom says money spent on chronic wound healing programs is money wasted, but a trio of investors is doubling down on CoDa Therapeutics Inc. based on Nexagon's performance in a Phase II trial in chronic venous leg ulcers.

Including last month's $19.2 million series B round, Domain Associates, GBS Venture Partners and BioPacificVentures have pitched in $42.2 million since CoDa was founded in 2006...